Share Email Print

Proceedings Paper

Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas
Author(s): Christian S. Betz; Winrich Rauschning; Evgueni P. Stranadko; Mikhail V. Riabov; Volker Albrecht; Nikolay E. Nifantiev; Colin Hopper
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Objectives: Basal cell carcinomas (BCCs) are the most common skin cancers, and incidence rates are still rising. Photodynamic Therapy (PDT) with mTHPC (Foscan®) has shown to be a promising alternative to other treatments with good cosmetic results. This study was performed to determine optimal treatment parameters for this indication. Methods: 117 patients with a total of 460 BCCs received mTHPC-PDT. The treatment parameters were varied as follows: Foscan® dose 0.03 - 0.15 mg/kg, drug-light interval (DLI) 1 - 96 hours, total energy density 20 - 120 J/cm2. The clinical outcomes were assessed 8 weeks after PDT following WHO guidelines. Results: The rate of complete remissions (CR) was 96.7% and the general cosmetic outcome rated very good. In the largest subgroup (n=80) with low-dose mTHPC (0.05 mg/kg mTHPC; 48 hours DLI; 50 J/cm2 total energy density), a CR rate of 100% was accomplished. Minor changes of the parameters (0.04 mg/kg mTHPC or 24 hours DLI) yielded similar results. Side effects were encountered in 52 out of 133 PDT sessions. They were more common in patients who had received high drug doses (0.06 - 0.15 mg/kg) and comprised pain and phototoxic reactions. 3 patients developed severe sunburns with subsequent scarring at the injection site following sunlight exposure 2-3 weeks after mTHPC administration. Conclusions: The data suggests that low-dose mTHPC-PDT is an effective treatment option for BCCs. If sensibly applied, it is well tolerated and provides mostly excellent cosmetic results. The evaluation of long term results is still to be undertaken.

Paper Details

Date Published: 13 July 2009
PDF: 9 pages
Proc. SPIE 7380, Photodynamic Therapy: Back to the Future, 73800P (13 July 2009); doi: 10.1117/12.822063
Show Author Affiliations
Christian S. Betz, Ludwig Maximilian Univ. Munich (Germany)
Univ. College London (United Kingdom)
Winrich Rauschning, Biolitec Pharma Ltd. (Ireland)
Evgueni P. Stranadko, Russian Ministry of Public Health (Russian Federation)
Mikhail V. Riabov, Russian Ministry of Public Health (Russian Federation)
Volker Albrecht, Biolitec AG (Germany)
Nikolay E. Nifantiev, Biolitec AG (Germany)
Colin Hopper, Ludwix Maximilian Univ. Munich (Germany)
Univ. College London (United Kingdom)

Published in SPIE Proceedings Vol. 7380:
Photodynamic Therapy: Back to the Future
David H. Kessel, Editor(s)

© SPIE. Terms of Use
Back to Top